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baumannii infections. Tigecycline, a glycylcycline antibiotic, is
active against A. baumannii and it has been used in the treatment
of VAP caused by this pathogen in some countries or regions.
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The advanced antimicrobial resistance of Gram-negative bacilli
(mainly A. baumannii, Pseudomonas aeruginosa, and extended
spectrum beta-lactamase producing Enterobacteriaceae, includ-
ing Klebsiella pneumoniae) has become a global public health
threat. The intrinsic or acquired antimicrobial resistance in these
clinically important pathogens is mediated with various mech-
anisms (production of beta-lactamases and/or enzymes inacti-
vating aminoglycosides, efﬂux pumps, lower permeability of the
outer membrane, mutations in antibiotic targets, etc.). Broad-
spectrum beta-lactam antibiotics have been considered the ﬁrst
choice for the treatment of patients with multiple drug resistant
A. baumannii and Pseudomonas aeruginosa infections. However,
the worrisome pattern of increasing antimicrobial resistance of
these pathogens has led to re-evaluation and use of intravenous
and aerosolized polymyxins (mainly colistin) in various parts of
the world. In addition, various agents with novel mechanisms
of antibacterial action have been investigated, although there
are no available clinical data regarding their effectiveness and
safety. Also, the developments in the advancing pattern of
antimicrobial resistance of Gram-negative bacilli has been asso-
ciated with the use of a diversity of deﬁnitions of multiple drug
resistant (MDR), extensively drug resistant (XDR), and pandrug
resistant (PDR) pathogens on which we have commented (Falagas
ME et al. Clin Microbiol Infect 2005;11:1049, J Med Microbiol
2006;55:1619, and Clin Infect Dis 2008;46:1121). Considering
various issues, the terms “pandrug resistance”, “extensive drug
resistance”, and “multidrug resistance” should designate resis-
tance of a pathogen to all, resistance to all but 1 or 2, and
resistance to at least three, respectively, classes of antimicrobial
agents, among those that are available at the time of use of
the deﬁnition in most parts of the world and are regarded as
potentially effective against the respective pathogen.
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Background and aims: Leishmaniasis is caused by parasitic proto-
zoa of the genus Leishmania; humans are infected via the bite of
phlebotomine sandﬂies. It is prevalent in 88 countries, affecting
an estimated 12 million people with approximately 2 million new
cases per year, 500,000 of which are Visceral Leishmaniasis (VL)
and l,500,000 Cutaneous form (CL), representing a signiﬁcant
rank among communicable diseases. Moreover, Leishmania/HIV
coinfection has been reported in 35 countries worldwide. There
are four main types of the disease: In CL, skin ulcers usually
form on exposed areas, which usually heal within a few months,
leaving scars. Diffuse cutaneous leishmaniasis (DCL) produces
disseminated and chronic skin lesions resembling those of lep-
romatous leprosy which is difﬁcult to treat. In muco-cutaneous
form (MCL), the lesions can partially or totally destroy the
mucous membranes of nose, mouth and throat cavities and sur-
rounding tissues. VL is characterized by high fever, substantial
weight loss, swelling of the spleen/liver and anaemia with high
fatality rate within two years. The aim of this study is to analyze
current situation of leishmaniasis as a neglected tropical disease
in the world, Eastern Mediterranean Region and Iran.
Methods: The global burden of leishmaniasis was discussed with
respect to ﬁnancial and political impacts; relation to poverty;
stigma of pathologies; effective implemented tools, available re-
sources and lack of input from pharmaceutical and biotechnology
companies to develop new drugs and vaccines. Criteria by which
different types of leishmaniasis could be prioritized as target
disease were set. These criteria included: incidence, prevalence
and severity of the disease, lack of response to available drugs;
the impact of treatment of individuals on control of transmission
and lack of other major parties involved in drug development.
There are no adequately effective therapies, but some encour-
aging results have been obtained with immuno-modulators plus
antimonials and herbal extracts. Immunogenicity clinical trials
are currently ongoing with whole killed Leishmania parasites,
second generation and DNA vaccines.
Results: According to the current data, the overall inci-
dence/prevalence rates, and social/ﬁnancial burdens of leish-
maniasis are high. The analysis of published trials indicates that
the available drugs are inadequate; the quality of most trials is
poor and requires both improvement and standardization. The
mechanism for controlling Leishmania infection to reach a stable
self healing process is a balanced immune response, however
immune stimulation during chemotherapy can enhance cure.
Conclusions: Neglected tropical diseases are a symptom of
poverty and disadvantage. With little political voice, neglected
leishmaniasis has a low proﬁle and status in public health pri-
orities. In addition, the problem of Leishmania/HIV coinfection
is spreading to the countries that are the world’s major foci of
leishmaniasis. There is an urgent need for new treatments for all
leishmaniasis. Immuno-chemotherapy with therapeutic vaccines
or immunomodulators has a strong potential to make an impact
as a new therapy with shortening duration and reducing dose
of drug treatment and preventing resistance. There is also a
need for safe, affordable and efﬁcacious novel chemotherapeu-
tics. The quality of clinical trials needs to be enhanced and
standardized.
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Background: Falciparum malaria is the most deadly among the
four main types of human malaria. Although great success has
been achieved since the launch of the National Malaria Control
Programme in 1955, malaria remains a serious public health
problem in China. This paper aimed to analyse the geographic
distribution, demographic patterns and time trends of falciparum
malaria in China.
Methods: The annual numbers of falciparum malaria cases dur-
ing 1992-2003 and the individual case reports of each clini-
cal falciparum malaria during 2004-2005 were extracted from
communicable disease information systems in China Center for
